Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Complex Mixtures
Biological Products
Clear Filters

Search Clinical Trials

30 Results
Completed
MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer
Patients will be screened within 6 weeks prior to Week 1. A total of 3 cohorts, consisting of 3 to 6 patients each, are planned to receive five to eight …
Baylor Role: Collaborator
Active, Not Recruiting
A Phase I/II Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells
TREATMENT PLAN: Standard Chemotherapy for Neuroblastoma: Standard therapy for neuroblastoma is given in 3 phases: induction, consolidation, and maintenance. For enrollment in this vaccine study patients and their physicians must …
Baylor Role: Lead Sponsor
Completed
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
To participate in this study, patients will need to have given informed consent to have a bone marrow transplant. Before receiving the tetanus vaccine, we would like to test the …
Baylor Role: Collaborator
Completed
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells
Previously, some of the cancer cells taken from the patients body were separated in the laboratory and a specially produced human virus (adenovirus) that carries the IL-2 gene was put …
Baylor Role: Lead Sponsor
Completed
Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer
OBJECTIVES: Primary - Evaluate the safety and tolerance of NY-ESO-1/LAGE-1 class-I and class-II vaccine administered subcutaneously in patients with androgen-independent metastatic prostate cancer. Secondary - Compare the response induced by …
Baylor Role: Lead Sponsor
Completed
Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection
There is an urgent need for new tools to control human hookworm infection and to reduce its burden of disease in developing countries. This is especially true for children and …
Baylor Role: Lead Sponsor
Completed
Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change
This study is a 43-month prospective, randomized, double-blind, placebo-controlled comparison of immunogenicity and reactogenicity elicited by BioThrax given by different routes of administration (SQ versus IM) and dosing regimens (as …
Baylor Role: Collaborator
Completed
Neuroblastoma Vaccine for Treatment of High-Risk Neuroblastoma After Chemotherapy
Tumor cells from subjects with high-risk neuroblastoma will be obtained at the time of presentation and initial diagnosis, during routine surveillance of bone marrow disease status, or at the time …
Completed
Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine
Before starting in the treatment part of this study, leukemia cells and skin fibroblasts will be collected from the patient - called "procurement" - to allow us to make the …
Baylor Role: Lead Sponsor
Completed
Control of Epidemic Influenza Through a School-based Influenza Vaccination Program
This study was conducted in three phases. The first phase spanned from 1998-2003 (PubMed ID:14706961; PubMed ID: 12915495) and the second phase spanned from 2003-2007 (PubMedID: 18401289; PubMed ID: 17698577). …
Baylor Role: Lead Sponsor